virus
ultramicroscop
acellular
metabol
inert
nucleoprotein
particl
contain
bundl
gene
strand
either
rna
dna
without
surround
lipidcontain
envelop
unlik
freeliv
bacteria
virus
oblig
intracellular
parasit
utilis
host
cell
machineri
propag
new
virus
caus
ailment
benign
common
wart
irrit
cold
deadli
bloodi
african
fever
henc
virus
term
acellular
parasit
cellular
host
virus
numer
invas
strategi
strain
uniqu
configur
surfac
molecul
enabl
enter
host
cell
precis
fit
surfac
molecul
molecul
target
cell
exampl
virus
caus
lassa
ebola
fever
aid
spread
easili
kill
swiftli
cure
vaccin
strain
viru
uniqu
surfac
antigen
structur
receptor
host
cell
life
cycl
consequ
genet
variat
varieti
mode
transmiss
effici
replic
abil
persist
within
host
virus
adapt
form
life
occupi
numer
ecolog
nich
result
widespread
diseas
human
livestock
plant
discoveri
novel
antivir
drug
deserv
great
effort
sever
review
publish
recent
year
state
discoveri
new
drug
differ
viral
infect
natur
resourc
role
tradit
medicin
develop
antivir
compound
also
discuss
differ
review
interestingli
found
tradit
medicin
like
ayurved
tradit
chines
medicin
tcm
chakma
medicin
good
sourc
potenti
antivir
drug
wide
varieti
activ
phytochem
includ
flavonoid
terpenoid
organosulfur
compound
limonoid
lignan
sulfid
polyphenol
coumarin
saponin
chlorophyllin
furyl
compound
alkaloid
polyin
thiophen
protein
peptid
found
therapeut
applic
differ
genet
function
divers
virus
antivir
mechan
agent
may
explain
basi
antioxid
activ
scaveng
capac
inhibit
dna
rna
synthesi
inhibit
viral
entri
inhibit
viral
reproduct
larg
number
candid
substanc
phytochem
synthet
deriv
identifi
combin
vitro
vivo
studi
differ
biolog
assay
chapter
review
differ
approach
method
use
discov
potenti
lead
molecul
antivir
substanc
natur
sourc
includ
extract
pure
compound
herbal
medicin
major
conclus
phytochem
medicin
plant
extract
import
sourc
antivir
agent
despit
continu
advanc
made
antivir
therapi
viral
diseas
becom
lead
caus
death
global
oblig
intracellular
parasit
virus
depend
metabol
pathway
host
cell
replic
sinc
virus
host
intim
connect
design
effect
antivir
attack
viral
enzym
replic
without
affect
host
cell
prove
difficult
advanc
molecular
biolog
revers
genet
past
two
decad
come
know
biochemistri
viru
replic
lead
ration
approach
search
antivir
agent
target
viru
bind
fusion
replic
intermedi
dnarna
polymeras
viral
assembl
protein
sinc
viral
enzym
crucial
diseas
progress
viru
replic
inhibitor
viral
enzym
desir
strategi
wellstudi
inhibitor
hiv
hsv
influenza
virus
target
host
cell
bind
betulin
acid
etc
uncoat
capsid
amantadin
deriv
pleconaril
replic
revers
transcriptas
inhibitor
like
zidovudin
abacavir
nevirapin
etc
integras
inhibitor
dna
rna
polymeras
inhibitor
acyclovir
cidofovir
ribavirin
etc
proteinas
involv
viral
polyprotein
precursor
assemblymatur
inhibitor
indinavir
ritonavir
rimantadin
etc
basi
strategi
numer
compound
test
differ
virus
past
decad
still
licens
antivir
market
rapid
advanc
viral
genom
gene
function
regul
well
ration
drug
design
led
develop
genebas
drug
induc
protect
antivir
immun
interfer
viral
replic
suppress
viral
gene
express
cleav
viral
mrna
sever
drug
candid
develop
recent
year
variou
virus
includ
hiv
although
genebas
agent
show
promis
antivir
agent
therapeut
efficaci
may
restrict
limit
deliveri
intracellular
site
viral
replic
vivo
nucleas
degrad
overview
medicin
plant
worldwid
effect
sourc
antimicrobi
drug
ancient
cultur
world
like
china
india
persia
reli
histor
continu
reli
medicin
plant
primari
health
care
recent
year
owe
fear
side
effect
common
drug
counter
medicin
huge
upsurg
peopl
prefer
use
natur
plant
product
prevent
treat
seriou
ailment
howev
sinc
scientif
background
provid
counter
herbal
product
qualiti
control
provid
consist
result
natur
plant
product
tradit
provid
modern
antimicrobi
anticanc
drug
pharmaceut
industri
still
bare
analys
tip
iceberg
effort
design
antimicrobi
drug
plant
thu
imper
search
use
phytochem
lose
herbal
resourc
upward
march
industrialis
tabl
fortun
mani
virus
uniqu
featur
structur
replic
cycl
potenti
target
evid
nucleosid
analogu
acycloguanosin
acyclovir
specif
block
certain
viral
enzym
herp
virus
play
key
role
trigger
diseas
owe
amaz
structur
divers
broad
rang
bioactiv
natur
product
explor
sourc
complementari
antivir
mani
report
inhibit
sever
step
replic
cycl
certain
cellular
factor
mani
dna
andor
rna
virus
mani
tradit
medicin
plant
use
indian
ayurveda
tcm
report
strong
antivir
activ
use
reduc
diseas
sever
research
interest
antivir
agent
start
second
world
war
europ
plant
found
effect
influenza
virus
embryon
egg
past
year
numer
broad
base
screen
programm
initi
differ
part
world
screen
antivir
activ
vitro
vivo
assay
one
hundr
british
colombian
medicin
plant
screen
antivir
activ
seven
virus
antivir
activ
corona
virus
rsv
para
influenza
hsv
observ
marin
alga
blue
green
alga
spirulina
studi
immunomodulatori
antimutagen
antivir
properti
cynovirin
n
kda
protein
blue
green
alga
shown
interact
inactiv
hiv
presenc
variou
sulfat
polysaccharid
group
extract
seawe
alga
shown
antihiv
antihsv
activ
sever
herbal
medicin
product
potenti
sourc
function
food
variou
bioactiv
like
immunomodulatori
antimicrobi
function
summaris
divers
methodolog
way
evalu
potenti
natur
compound
antivir
activ
mainli
common
viral
diseas
vitro
assay
usual
exploit
viru
abil
infect
replic
specif
cell
line
cell
cultur
system
cell
cultur
system
provid
rapid
less
cumbersom
method
grow
virus
higher
titr
vaccin
strain
cultur
revers
genet
test
antivir
compound
exampl
cell
line
characteris
routin
use
common
virus
provid
tabl
indirect
assay
usual
first
step
screen
larg
number
compound
antivir
activ
base
observ
viru
infect
multipl
result
cytopath
effect
due
either
releas
viru
induct
apoptosi
result
host
immun
respons
inhibit
cpe
presenc
test
compound
could
due
inhibit
viru
replic
variou
indirect
test
develop
modifi
individu
virus
visual
observ
cytopath
effect
cpe
visual
observ
cpe
help
microscop
well
plate
cell
infect
viru
presenc
absenc
drug
run
duplic
broadli
method
test
test
compound
initi
evalu
test
differ
exampl
ngml
mgml
standard
use
h
monolay
confluent
appropri
cell
medium
drain
concentr
test
compound
placebo
ad
immedi
viru
infect
case
effect
drug
need
test
pretreat
cell
treat
test
compound
min
h
viru
infect
plate
seal
incub
standard
time
period
requir
induc
near
maxim
viral
cpe
everi
h
end
experi
plate
visualis
microscop
chang
cell
appear
compar
normal
control
cell
cours
experi
test
compound
viru
treatment
give
idea
maximum
dose
drug
caus
minimum
cell
toxic
chang
may
enlarg
granul
round
detach
plate
chang
given
design
toxic
pvh
partial
toxic
heavi
ph
partial
toxic
heavi
p
partial
ps
partial
toxic
slight
conform
degre
cytotox
seen
cell
inhibitori
cytotox
concentr
ic
endpoint
viru
inhibitori
concentr
ec
determin
gener
select
index
calcul
si
ic
ec
si
three
indic
potenti
antivir
activ
test
compound
evalu
increas
concentr
neutral
red
dye
uptak
compound
show
si
three
fourfiv
log
dilut
test
compound
eg
ngml
etc
use
triplic
plate
monolay
cell
treat
drug
min
h
follow
viru
adsorpt
pretreat
drug
ad
viru
adsorpt
postinfect
treatment
plate
seal
incub
cpe
observ
microscop
untreat
infect
control
develop
cpe
approxim
h
known
posit
control
drug
evalu
parallel
valid
test
exampl
ribavirin
use
case
dengu
influenza
measl
rsv
cidofovir
adenovirus
interferon
sar
cpe
read
microscop
neutral
red
ad
medium
live
healthi
cell
take
dye
plate
read
micropl
reader
dual
wavelength
nm
differ
read
use
elimin
background
ec
concentr
drug
inhibit
viru
observ
brief
protocol
neutral
red
uptak
cytotox
assay
plate
contain
mammalian
cell
line
cultur
medium
plate
concentr
cellsml
ii
cell
remov
incub
ae
h
plate
cultur
medium
replac
freshli
prepar
cultur
medium
ml
well
ad
blank
control
group
neg
control
group
increas
concentr
test
substanc
viru
infect
done
experiment
well
anoth
rapid
sensit
vitro
procedur
evalu
antivir
agent
base
spectrophotometr
assess
viabil
virusinfect
mockinfect
cell
via
situ
reduct
tetrazolium
dye
bromid
mtt
prove
similar
sensit
like
plaqu
reduct
assay
mitochondri
enzym
viabl
cell
convert
yellow
water
solubl
dye
mt
mtt
solubl
purpl
colour
insolubl
formazan
quantit
amount
formazan
product
present
well
microtitr
plate
determin
spectrophotometr
nm
toxic
test
compound
host
cell
measur
concurr
microtitr
plate
data
analys
statist
softwar
programm
along
determin
efficaci
ic
toxic
tc
select
therapeut
index
ti
compound
significantli
simplifi
assay
procedur
also
allow
evalu
larger
number
compound
time
method
use
success
high
throughput
screen
assay
drug
vero
cell
abil
compound
inhibit
hsvinduc
cell
kill
measur
five
day
postinfect
use
tetrazolium
dye
mt
mtt
follow
method
describ
briefli
cell
cellsml
seed
tissu
cultur
plate
h
period
incub
medium
remov
replenish
ml
medium
contain
increas
concentr
compound
serial
dilut
twofold
cell
control
ml
medium
ad
three
five
day
incub
medium
remov
ml
mtt
solut
test
drug
concentr
inhibit
viru
yield
one
log
determin
data
test
compound
antivir
activ
express
select
index
si
ic
divid
ec
gener
si
greater
indic
posit
antivir
activ
although
factor
low
si
posit
control
also
taken
consider
compound
confirm
si
valu
greater
may
evalu
addit
strain
origin
viru
inhibit
order
fulli
determin
spectrum
antivir
activ
compound
potenti
antivir
test
compound
screen
direct
assay
measur
viral
replic
inhibit
titr
direct
assay
measur
reduct
viral
titr
presenc
test
compound
compar
untreat
cell
inhibit
cytopath
effect
cell
monolay
infect
viru
measur
endpoint
titrat
method
also
help
determin
virucid
activ
preincub
test
compound
viru
endpoint
titrat
perform
confluent
monolay
cell
cell
per
well
infect
serial
dilut
tcd
ml
viru
suspens
viru
allow
absorb
h
serial
twofold
dilut
extract
test
compound
mainten
medium
supplement
foetal
bovin
serum
antibiot
ad
plate
incub
viral
cpe
record
light
microscopi
four
five
day
import
run
cytotox
control
uninfect
treat
cell
cell
control
uninfect
untreat
cell
treatment
concentr
viru
control
infect
untreat
toxic
dose
ct
test
extract
compound
consid
dilut
caus
destruct
monolay
cell
viru
titr
determin
antivir
activ
express
viru
titr
reduct
maximum
nontox
dose
mntd
test
extract
substanc
highest
concentr
affect
monolay
test
condit
method
viru
titr
reduct
factor
rf
ratio
viru
titr
reduct
absenc
presenc
mntd
test
sampl
indic
pronounc
antivir
activ
suitabl
select
criteria
investig
said
extract
compound
import
antivir
activ
present
least
two
subsequ
dilut
test
substanc
otherwis
activ
like
due
toxic
activ
virucid
extracellular
virucid
activ
also
determin
titrat
method
residu
infecti
viru
room
temperatur
incub
test
compound
viru
suspens
tcd
ml
h
figur
assay
perform
virus
antibodi
avail
either
commerci
inhous
provid
estim
quantiti
viru
though
differenti
infecti
noninfecti
viral
particl
thu
drug
affect
later
stage
viru
matur
bud
may
give
good
estim
viral
inhibit
briefli
untreat
drugtreat
cell
infect
known
concentr
viru
moi
viru
adsorpt
min
viru
remov
cell
wash
media
fresh
media
ad
cell
incub
h
tent
time
requir
achiev
cpe
media
remov
cell
wash
pb
cell
fix
paraformaldehyd
pb
room
temperatur
wash
pb
cell
permeablis
either
aceton
triton
wash
twice
pb
cell
block
bsa
pb
min
follow
incub
mous
rabbit
antibodi
specif
viral
protein
h
sever
step
wash
cell
incub
fluoresc
tag
secondari
antibodi
bsa
h
cell
wash
three
four
time
pb
visualis
fluoresc
microscop
fluoresc
compar
untreat
drugtreat
cell
altern
quantit
cell
trypsinis
treatment
fix
paraformaldehyd
cell
wash
pb
permeablis
label
fluorescenttag
antibodi
follow
propidium
iodid
mgml
pi
pb
cell
count
fluoresc
activ
cell
counter
fluoresc
posit
percentag
quantit
measur
pi
indirectli
measur
cytotox
caus
drug
viru
infect
enzym
link
immunosorb
assay
elisa
elisa
assay
allow
detect
viral
antigen
antibodi
use
solidphas
assay
system
although
qualit
offer
rapid
sensit
specif
method
detect
gross
quantit
viru
absolut
quanit
possibl
seri
predetermin
viral
titr
use
get
elisa
read
match
unknown
sampl
calcul
estim
quantiti
viru
sampl
untreat
drugtreat
method
differenti
infecti
noninfecti
viru
particl
result
drug
affect
earlier
latter
stage
viral
replic
matur
may
understood
figur
vitro
antivir
test
protocol
wwwelseviercomlocatenbt
briefli
untreat
drugtreat
cell
infect
known
concentr
viru
adsorb
h
wash
incub
two
four
day
depend
virusinduc
cpe
viru
harvest
freezethaw
centrifug
supernat
dilut
sampl
diluent
use
elisa
experi
well
stripplat
coat
virusspecif
antibodi
ml
control
test
sampl
ad
follow
h
incub
room
temperatur
ml
conjug
contain
enzym
label
virusspecif
antibodi
wash
five
time
ml
substrat
ad
incub
dark
min
room
temperatur
assay
employ
horseradish
peroxidas
alkalin
phosphatas
bdgalactosidas
reaction
stop
stop
solut
kit
usual
h
absorb
read
taken
photometr
od
altern
drug
treatment
viru
infect
perform
format
instead
prepar
viru
supernat
quadrupl
monolay
microtitr
plate
overlaid
log
dilut
test
compound
follow
infect
viru
h
incub
monolay
fix
glutaraldehyd
pb
assay
protein
specif
viru
cell
surfac
elisa
perform
monoclon
antibodi
mab
specif
protein
correspond
viru
strain
protein
horseradish
peroxidas
conjug
bio
rad
hercul
ca
optic
densiti
od
measur
express
percentag
nondrugtr
virusinfect
cell
viru
control
concentr
caus
reduct
optic
densiti
valu
ec
evalu
graphic
plot
select
index
si
determin
ratio
ic
ec
plaqu
assay
one
reliabl
oldest
method
titrat
infecti
viru
particl
sampl
effect
drug
reduc
plaqueform
unit
pfu
viru
compar
control
indic
antivir
activ
variou
protocol
standardis
differ
virus
though
principl
figur
vero
cell
grown
suitabl
cell
cultur
media
incub
h
confluent
cell
monolay
infect
plaqueform
unit
pfu
viru
h
incub
allow
viral
adsorpt
cell
wash
phosphat
buffer
salin
pb
overlaid
agar
cell
cultur
medium
contain
twofold
dilut
extract
test
compound
recultur
plaqu
appear
final
monolay
cell
fix
formalin
stain
dri
number
plaqu
microscop
count
percentag
inhibit
plaqu
format
mean
number
plaqu
control
mean
number
plaqu
test
mean
number
plaqu
control
effect
concentr
plaqu
reduct
ec
lowest
extract
concentr
reduc
plaqu
number
treat
cultur
compar
untreat
one
inhibitori
concentr
ic
extract
concentr
requir
reduc
viru
plaqu
number
calcul
recent
studi
differ
herbal
prepar
cold
aqueou
hot
aqueou
ethanol
acid
ethanol
methanol
plaqu
reduct
assay
show
aqueou
extract
p
suffruticosa
ethanol
extract
melia
toosendan
inhibit
attach
replic
indic
herb
potenti
sourc
new
antihsv
compound
hemagglutin
assay
measur
viral
titr
hemagglutin
assay
ha
quantit
hemagglutin
protein
virus
viral
famili
surfac
envelop
protein
abl
agglutin
stick
human
anim
red
blood
cell
rbc
bind
nacetylneuramin
acid
rbc
form
type
lattic
case
contrast
plaqu
assay
ld
schemat
represent
viral
plaqu
assay
modifi
wwwelseviercomlocatenbt
infect
viru
replic
requir
assay
easi
simpl
rapid
method
appli
larg
amount
sampl
detail
condit
depend
type
viru
virus
bind
rbc
certain
ph
valu
other
certain
ionic
strength
figur
test
compound
inhibit
viru
replic
thu
viral
titr
ha
valu
reduc
briefli
viru
dilut
eg
twofold
appli
rbc
dilut
eg
step
approxim
min
often
virus
neuraminidas
activ
detach
viru
rbc
lattic
form
part
count
titr
calcul
per
ad
well
except
first
well
row
ml
antigen
tissu
cultur
fluid
viru
drug
treat
drug
control
infect
plate
ad
first
two
well
row
twofold
dilut
made
transfer
ml
second
well
column
use
multichannel
micropipett
proceed
till
ninth
column
remain
ml
discard
ninth
column
ml
rbc
ad
well
mix
manual
agit
plate
thoroughli
plate
incub
min
room
temperatur
cell
control
check
complet
settl
rbc
result
record
ha
sheet
rbc
form
button
ring
bottom
well
record
hemagglutin
occur
rbc
remain
suspens
record
use
symbol
highest
dilut
viru
caus
complet
hemagglutin
consid
endpoint
ha
titrat
ha
titr
reciproc
dilut
viru
last
well
complet
hemagglutin
figur
sampl
virus
preincub
drug
certain
dilut
viral
particl
may
lose
abil
agglutin
erythrocyt
indic
interact
drug
viral
ha
figur
real
time
pcr
engend
wider
accept
pcr
studi
viral
load
due
improv
rapid
low
interassay
intraassay
variabl
sensit
reproduc
reduc
risk
carryov
contamin
method
involv
direct
measur
amount
pcr
product
produc
reaction
progress
mathemat
analysi
data
comparison
control
reaction
contain
known
amount
templat
allow
one
calcul
amount
input
dna
initi
reaction
sever
diseas
shown
correl
viral
load
make
realtim
pcr
quantit
use
studi
simpli
presenc
viru
role
viral
reactiv
persist
progress
diseas
properti
success
adapt
screen
potenti
antivir
test
compound
vitro
fold
decreas
viral
genet
materi
presenc
drug
measur
antivir
activ
briefli
rna
virus
initi
cdna
prepar
use
stan
order
analys
data
report
fam
fluoresc
automat
normalis
passiv
refer
avoid
measur
nonpcrrel
fluoresc
threshold
set
baselin
threshold
cycl
valu
ct
defin
cycl
number
fluoresc
pass
fix
threshold
statist
signific
increas
fluoresc
first
detect
qpcr
amplif
standard
curv
test
sampl
design
ct
valu
plot
versu
log
standard
concentr
calcul
interpret
antivir
effect
higher
ct
valu
correspond
drugtreat
sampl
compar
untreat
sampl
prove
antivir
effect
drug
viral
load
particl
fold
decreas
calcul
standard
plot
ct
valu
found
less
case
drugtreat
sampl
rather
untreat
one
data
ic
ic
may
also
calcul
get
reduct
viral
particl
fold
chang
cell
cultur
experiment
design
hbv
human
hbvtransfect
cell
line
routin
cultur
dulbecco
modifi
eagl
medium
dmem
gibco
usa
supplement
vv
foetal
bovin
serum
gibco
usa
unitml
penicillin
mgml
streptomycin
mm
lglutamin
humidifi
incub
co
cell
seed
tissu
cultur
plate
approxim
well
maintain
h
extract
treatment
differ
concentr
allow
hbv
dna
level
stabilis
cell
medium
hepg
cell
collect
right
first
dose
day
day
treatment
duplic
store
analysi
hepat
b
surfac
antigen
hbsag
hepat
b
e
antigen
hbeag
hbv
dna
level
cell
toxic
cytotox
effect
extract
toward
hepg
evalu
use
mtt
assay
determin
drug
concentr
affect
cell
viabil
drug
concentr
use
subsequ
assay
determin
hbsag
hbeag
incub
variou
concentr
extract
co
day
cultur
medium
collect
concentr
hbsag
hbeag
detect
enzymelink
immunosorb
assay
elisa
kit
kehua
inc
china
follow
manufactur
protocol
inhibit
ratio
od
control
od
sampl
od
control
analysi
hbv
dna
intracellular
hbv
dna
analysi
cell
plate
lyse
mlwell
lysi
buffer
guanidin
isothiocyan
sarkocyl
cell
cm
dish
lyse
ml
lysi
buffer
cellular
dna
prepar
previous
describ
dna
mg
digest
ecori
electrophores
agaros
gel
transfer
nitrocellulos
membran
purifi
kb
ecori
hbv
dna
fragment
label
digoxigenin
use
detect
follow
manufactur
protocol
roch
inc
usa
hbv
dna
copi
number
determin
quantit
pcr
pcr
reaction
perform
biorad
icycl
biorad
usa
follow
manufactur
manual
oligonucleotid
sequenc
primer
follow
hbv
upstream
downstream
pcr
carri
ml
reaction
volum
contain
ml
rpcr
buffer
ml
mm
mg
ml
mm
dntp
ml
mm
primer
ml
sybr
sybr
green
ml
calibr
ml
uml
taqe
takara
bio
japan
ml
ddh
ml
hbv
dna
initi
incub
activ
taq
polymeras
cycl
amplif
conduct
use
follow
programm
pcr
product
final
held
analysi
gapdh
gene
use
dna
standard
primer
gapdh
follow
rtpcr
standard
gener
use
serial
dilut
known
dna
hbv
dna
copi
number
normalis
gapdh
calcul
icycl
iq
tm
realtim
system
softwar
version
window
biorad
usa
accord
standard
curv
hbv
dna
inhibit
rate
copi
number
controlcopi
number
studi
sampl
copi
number
control
compound
also
evalu
activ
challeng
differ
amount
viru
like
hcmv
vzv
rang
low
high
multipl
infect
time
addit
time
remov
compound
ad
remov
cultur
variou
time
preinfect
postinfect
comparison
known
viral
inhibitor
allow
determin
rel
point
viru
life
cycl
inhibit
immedi
earli
earli
late
function
dna
polymeris
etc
standard
techniqu
typic
use
earli
process
determin
mechan
action
allow
one
narrow
smaller
target
window
activ
experiment
also
allow
easi
way
determin
compound
act
uniqu
novel
mechan
compar
known
inhibitor
furthermor
time
remov
studi
allow
one
determin
revers
compound
activ
analysi
viral
dna
effect
compound
product
viral
dna
evalu
use
variou
hybridis
techniqu
pcr
taqman
pcr
analysi
viral
protein
effect
compound
product
immedi
earli
earli
late
viral
protein
evalu
use
western
blot
andor
flow
cytometri
select
characteris
drugresist
viru
isol
resist
viru
isol
select
tissu
cultur
serial
passag
viru
presenc
gradual
increas
concentr
compound
resist
evalu
perform
avail
cell
line
varieti
viru
isol
addit
resist
select
evalu
use
combin
antivir
agent
evalu
rel
abil
viru
becom
resist
multipl
agent
might
use
clinic
basi
target
site
infect
diseas
present
variou
anim
model
use
differ
virus
name
mous
guinea
pig
ferret
rabbit
primat
anim
model
studi
hsv
broad
host
rang
hsv
allow
use
differ
anim
model
studi
virus
ideal
anim
model
would
abl
recreat
aspect
human
diseas
obvious
attain
still
term
abil
hsv
establish
localis
initi
infect
follow
neuron
spread
establish
latenc
number
use
model
exist
understand
diseas
human
appropri
model
latenc
must
allow
viru
reactiv
similar
human
rabbit
guinea
pig
approxim
ideal
situat
although
suffer
limit
expens
third
model
mous
reason
cost
use
extens
suffer
lack
effici
vivo
reactiv
three
anim
system
extens
use
gener
vast
major
data
avail
hsv
latenc
reactiv
model
also
exist
hsv
infect
mice
provid
good
model
human
diseas
describ
differ
mous
model
well
anim
provid
receptor
hsv
entri
express
viral
glycoprotein
influenc
diseas
pathogen
man
test
vivo
toxic
efficaci
herbal
product
anim
sever
model
develop
commonli
use
method
vivo
toxic
determin
dermal
toxic
test
extract
substanc
usual
done
skin
irrit
test
efficaci
extract
compound
measur
cutan
lesion
develop
guinea
pig
figur
dermal
toxic
herbal
extract
extractbas
cream
test
guinea
pig
either
sex
g
remov
bodi
hair
dorsal
side
anim
ba
nake
skin
cm
wash
warm
water
dri
abrad
dermal
sevenstar
needl
extract
extractbas
cream
differ
potenc
like
appli
abrad
area
cohort
anim
n
rate
g
per
anim
h
cream
remov
warm
water
anim
examin
erythema
oedema
h
later
next
h
studi
extract
potenc
induc
cutan
lesion
dorsal
skin
guinea
pig
prepar
abrad
abrad
area
divid
four
quadrant
quadrant
infect
ml
dilut
anim
n
observ
day
typic
herp
lesion
develop
basi
initi
result
amount
stock
viru
determin
usual
ml
pfu
infect
cm
obtain
consist
lesion
develop
lesion
develop
cohort
anim
n
infect
treat
extract
extractbas
cream
ii
wtwt
acyclovir
cream
iii
base
cream
g
per
dose
infect
area
steril
cotton
swab
twice
daili
period
figur
extent
lesion
score
daili
follow
lesion
infect
area
lesion
infect
area
lesion
infect
area
lesion
entir
infect
area
test
vivo
efficaci
extract
formul
genit
herp
model
develop
random
breed
balbc
femal
mice
femal
sigmodon
hispidu
cotton
rat
intravagin
inocul
anaesthetis
inbr
mice
rat
oneweek
acclimatis
room
temperatur
ae
anim
anim
dilut
inocul
ml
viru
stock
vagina
size
needl
observ
day
develop
vagin
lethal
determin
median
lethal
dose
ld
test
efficaci
extract
formul
fresh
batch
anim
infect
ld
dose
viru
pfu
describ
follow
inocul
vagin
cotton
swab
sampl
collect
anim
transfer
ml
pb
store
anim
divid
test
group
differ
potenc
posit
control
group
acyclovir
neg
control
group
solvent
base
cream
one
treatment
vivo
test
protocol
antihsv
extractag
wwwelseviercomlocatenbt
extract
formul
vagin
tract
cotton
swab
dose
mg
per
mous
twice
daili
period
mortal
number
day
mortal
occur
record
day
one
follow
complet
treatment
well
deceas
anim
immedi
follow
death
vagin
swab
sampl
collect
figur
vagin
sampl
dilut
five
time
mem
use
infect
vero
cell
sampl
gave
posit
cpe
consid
posit
polysaccharid
lignincarbohydr
complex
prunella
vulgari
test
plaqu
reduct
assay
show
strong
activ
complex
block
hsv
bind
penetr
cream
semipurifi
fraction
p
vulgari
show
signific
reduct
p
skin
lesion
anim
p
mortal
skin
lesion
guinea
pig
model
genit
infect
model
balbc
mice
indic
complex
potent
antihsv
activ
fast
simpl
reactiv
model
studi
ocular
herpesviru
infect
latenc
success
establish
gordon
et
al
new
zealand
femal
rabbit
kg
follow
topic
anaesthesia
proparacain
eye
drop
unscarifi
rabbit
eye
inocul
suspens
thymidinekinaseposit
strain
pfuey
lower
fornix
follow
topic
anaesthesia
eye
drop
establish
latenc
reactiv
manner
similar
mous
pathogen
strain
mckrae
success
inocul
eye
found
day
typic
herpet
dendrit
ulcer
signific
titr
pfuml
viral
shed
determin
neutralis
test
satisfactori
anaesthesia
globe
proptos
wooden
cotton
applic
oper
microscop
use
facilit
surgic
manipul
intrastrom
inject
short
bevel
needl
attach
tuberculin
syring
inject
central
corneal
stroma
one
group
receiv
deionis
steril
endotoxinfre
water
anoth
group
get
ml
air
third
group
receiv
inject
three
group
needl
care
withdrawn
proptos
globe
gentli
return
orbit
gentl
digit
pressur
anterior
chamber
inject
deionis
steril
water
made
limbu
insert
anterior
chamber
parallel
iri
plane
needl
care
withdrawn
insert
site
press
cotton
swab
avoid
aqueou
loss
pressur
also
return
proptos
globe
proper
place
orbit
topic
administr
ml
deionis
steril
water
made
onto
cornea
proptos
globe
pipett
globe
return
orbit
gentl
digit
pressur
viral
shed
detect
latent
reactiv
induc
shed
tear
film
determin
swab
eye
two
day
treatment
consecut
day
treatment
eye
swab
mix
ml
mem
modifi
eagl
medium
earl
salt
newborn
calf
serum
penicillinstreptomycin
fungizon
vortex
eluant
plate
onto
vero
cell
monolay
adsorpt
period
addit
ml
media
ad
well
plate
examin
daili
seven
day
progress
cpe
characterist
random
isol
confirm
neutralis
infect
rabbit
eye
lead
latent
infect
viru
recov
trigemin
nerv
ganglia
follow
explant
cocultiv
indic
cell
addit
viru
sporad
recov
eye
follow
period
latenc
particular
use
fact
reactiv
effici
induc
iontophoresi
epinephrin
eye
model
import
establish
requir
lat
express
effici
reactiv
footpaddors
root
ganglia
model
mous
eyetrigemin
ganglia
model
second
murin
model
latenc
involv
infect
cornea
follow
viru
latenc
trigemin
ganglia
footpad
model
latent
hsv
genom
express
lat
latenc
associ
transcript
portion
neuron
maintain
viru
recov
cocultiv
explant
ganglia
interest
variat
method
come
closer
vivo
method
latent
infect
mice
transient
expos
hyperthermia
trigemin
ganglia
excis
section
assay
presenc
observ
viru
immunohistochem
method
genet
engin
recombin
viru
express
marker
genom
use
vagin
inocul
femal
guinea
pig
result
obviou
primari
infect
mortal
follow
recoveri
survivor
primari
infect
period
display
vesicular
recrudesc
vagin
area
infecti
viru
andor
viral
dna
recov
although
reactiv
reliabl
induc
fact
spontan
reactiv
much
higher
frequenc
make
attract
system
compar
analysi
influenc
viral
gene
reactiv
recombin
virus
investig
eye
toward
attempt
identifi
featur
import
differ
valu
guinea
pig
studi
drug
vaccin
effici
aspect
experiment
pathogenesi
make
extrem
valuabl
promis
system
respiratori
syncyti
viru
respiratori
syncyti
viru
rsv
member
famili
paramyxovirida
subfamili
pneumovirina
nonseg
neg
strand
genom
nucleotid
strain
nucleocapsid
within
lipid
envelop
irregular
size
shape
virion
contain
two
major
surfac
glycoprotein
fusion
protein
attach
protein
along
minor
hydrophob
protein
viru
two
major
antigen
group
b
dissimilar
attach
protein
related
relat
virus
bovin
ovin
caprin
rsv
mice
pneumonia
viru
turkey
rhinotrach
viru
rsv
structur
function
similar
parainfluenza
virus
littl
antigen
sequenc
relationship
distantli
relat
orthomyxovirida
influenza
viru
children
infect
first
year
life
month
age
children
infect
least
two
infect
incub
period
four
five
day
transmiss
probabl
occur
via
fomit
aerosol
viremia
pulmonari
involv
occur
initi
uncommon
subsequ
infect
except
bone
marrow
transplant
recipi
elderli
patient
viru
may
shed
long
day
protect
immun
respons
infect
individu
last
month
develop
vaccin
formalin
inactiv
subsequ
vaccin
children
end
disastr
result
till
date
success
sever
anim
model
rsv
infect
develop
use
primat
cotton
rat
mice
calv
guinea
pig
ferret
hamster
aim
know
mechan
diseas
test
efficaci
safeti
drug
candid
vaccin
prophylact
therapeut
rsv
multipl
anim
model
need
human
rsv
multifacet
diseas
whose
clinic
manifest
sequela
depend
upon
age
genet
makeup
immunolog
statu
singl
human
subpopul
form
rsv
diseas
manifest
singl
anim
model
duplic
form
rsv
diseas
henc
choic
anim
model
govern
specif
manifest
diseas
studi
thu
singl
anim
model
duplic
aspect
primari
rsv
diseas
man
cost
avail
opposit
anim
right
activist
restrict
studi
rsv
primat
model
particularli
chimpanze
primari
advantag
model
calf
natur
host
rsv
speci
cotton
rat
high
permiss
reliabl
predictor
prophylact
therapeut
strategi
mous
wide
avail
specialis
strain
reagent
guinea
pig
best
parallel
reactiv
airway
diseas
ferret
produc
agedepend
pulmonari
infect
utilis
calf
cotton
rat
mous
guinea
pig
ferret
model
probabl
increas
rel
strength
model
becom
well
defin
femal
balbc
mice
sedat
ketamin
xylazin
infect
intranas
inocul
pfu
rsv
rsv
infect
confirm
measur
titr
lung
evalu
effect
inhibit
no
activ
vivo
model
rsv
infect
perform
absenc
presenc
amt
sigma
chemic
lname
nnitrolarginin
methyl
ester
sigma
chemic
specif
inhibitor
ino
nonspecif
inhibitor
no
isoform
respect
agent
given
ip
daili
four
day
begin
h
rsv
infect
follow
dose
mgkg
amt
mgkg
lname
shown
investig
preliminari
studi
experiment
protocol
result
inhibit
product
mous
system
control
mice
receiv
normal
salin
intraperiton
similar
manner
schedul
basi
preliminari
doserespons
timerespons
studi
experi
use
no
inhibitor
perform
day
rsv
infect
peak
viral
replic
primari
rsv
infect
initi
describ
nasal
tissu
chimpanze
genet
heterogen
among
outbr
anim
statist
insignific
data
verif
publish
observ
laboratori
possibl
owe
limit
number
anim
thu
rais
question
scientif
valid
experi
experiment
rsv
infect
also
describ
owl
monkey
rhesu
monkey
african
green
monkey
cebu
monkey
squirrel
monkey
bonnet
monkey
baboon
purchas
mainten
cost
speci
high
handl
cumbersom
though
unlik
chimpanze
speci
use
termin
experiment
thu
allow
detail
virolog
histolog
studi
pulmonari
rsv
diseas
lack
inbreed
speci
limit
studi
none
develop
clinic
radiolog
sign
pulmonari
rsv
diseas
except
owl
monkey
develop
mild
rhinorrhea
use
african
green
monkey
pulmonari
diseas
develop
histolog
similar
human
howev
lack
suffici
number
anim
lack
inbreed
scarciti
immunolog
reagent
suggest
secondari
model
cotton
rat
uniformli
suscept
pulmonari
infect
thu
becom
use
model
longterm
studi
permiss
per
input
dose
viru
respons
develop
serum
antibodi
titr
higher
mous
parallel
human
recent
work
studi
combin
antiviralantiinflammatori
approach
suggest
modul
lung
inflamm
addit
clearanc
viru
requir
rapid
revers
clinic
diseas
clinic
trial
plan
test
approach
although
inbr
cotton
rat
commerci
avail
lack
reagent
plasma
protein
antigen
cytokin
congen
transgen
knockout
strain
limit
use
diseas
caus
rsv
bovin
rsv
sever
common
characterist
suggest
calf
may
use
model
human
rsv
diseas
exampl
virus
caus
acut
diseas
respiratori
tract
induc
incomplet
immun
respons
permit
repeat
life
long
infect
caus
epidem
winter
attenu
high
level
matern
deriv
antibodi
caus
sever
pulmonari
diseas
neonat
calf
model
howev
mani
drawback
like
cost
purchas
maintain
anim
lack
inbr
strain
lack
specif
reagent
addit
two
characterist
clinic
diseas
caus
bovin
rsv
calv
rais
concern
use
first
bovin
rsv
commonli
caus
fever
human
rsv
unknown
whether
due
differ
virus
host
respons
second
bacteri
pasteurella
haemophilu
mycoplasm
coinfect
common
complic
bovin
rsv
infect
wherea
coinfect
human
rsv
rare
anim
quantit
virolog
studi
report
syrian
hamster
although
rsv
replic
lung
nose
rel
permiss
hamster
equival
mous
less
cotton
rat
coat
chanock
examin
sever
speci
includ
four
strain
inbr
mice
balbc
akr
determin
permiss
pulmonari
viral
infect
found
none
four
mice
develop
cf
antibodi
one
strain
akr
develop
neutralis
antibodi
princ
et
al
princ
et
al
found
inbr
strain
includ
four
test
earlier
permiss
rsv
infect
lung
nose
level
viral
replic
vari
two
order
magnitud
least
permiss
cbacahn
permiss
strain
permiss
strain
less
sensit
cotton
rat
mous
model
sever
advantag
speci
like
avail
inbr
congen
transgen
knockout
strain
specif
reagent
allow
identif
quantit
cell
type
immunoglobulin
cytokin
rel
low
purchas
mainten
cost
although
prophylact
therapeut
formul
yet
licens
basi
studi
lot
inform
rsv
immunolog
emerg
review
see
rsv
replic
high
titr
nasal
tissu
ferret
age
viru
replic
lung
infant
anim
although
rapidli
decreas
permiss
lung
sever
limit
util
ferret
provid
intrigu
model
age
depend
sever
rsv
diseas
human
despit
fact
ferret
model
disadvantag
similar
guinea
pig
primat
model
lack
inbr
strain
immunolog
reagent
model
agedepend
pulmonari
infect
describ
thu
offer
potenti
tool
dissect
mechan
agedepend
diseas
human
inbr
femal
balbc
mice
week
old
use
anim
anaesthetis
intraperiton
inject
ml
ketamin
rompunsolut
equal
amount
rompun
solut
ketamin
solut
mix
rate
pb
infect
intranas
pfu
ml
influenza
viru
infect
mice
influenza
viru
preincub
specif
drug
either
ml
ml
viru
incub
either
ml
specif
drug
mg
ml
ml
pb
min
room
temperatur
five
mice
treat
time
inhal
chamber
singl
mice
treat
inhal
tube
five
tube
connect
central
cylind
overal
volum
pari
nebulis
aerosol
nebul
art
connect
either
inhal
chamber
central
tube
cylind
specif
extract
mgml
buffer
solut
pressur
bar
given
min
roughli
ml
chamber
extract
dissolv
steril
ddh
stock
solut
mg
extractml
distil
water
incub
h
water
bath
balbc
mice
place
tubecylind
expos
ml
aerosolis
extract
min
three
time
day
pm
treatment
perform
five
day
ten
minut
first
treatment
mice
infect
influenza
balbc
control
treat
amount
steril
ddh
viru
infect
gener
health
statu
anim
control
twice
day
furthermor
anim
weight
everi
day
mice
sacrif
lost
initi
weight
anim
monitor
day
infect
monitor
bodi
temperatur
gross
motor
activ
anim
perform
thevitalview
softwar
hardwar
system
mini
mitter
usa
allow
data
acquisit
physiolog
paramet
hardwar
includ
transmitt
emitt
receiv
system
emitt
collect
data
temperatur
gross
motor
activ
lifetim
anim
temperatur
sensit
devic
alter
puls
rate
respons
temperatur
chang
vital
view
system
record
averag
rate
convert
temperatur
use
temperatur
calibr
valu
specif
unit
vital
gross
motor
activ
measur
provid
basic
index
movement
mice
implant
emitt
mous
move
movement
implant
emitt
result
subtl
chang
transmit
signal
small
chang
detect
receiv
via
telemetri
regist
connect
comput
activ
count
experi
vital
view
softwar
record
index
movement
everi
min
produc
longitudin
record
activ
implant
emitt
mice
anaesthetis
intraperiton
inject
ml
ketaminerompun
ventral
surfac
abdomen
shave
midlin
abdomin
skin
incis
made
cm
diaphragm
cm
length
abdomen
open
cm
incis
along
linea
alba
emitt
posit
abdomin
caviti
incis
close
two
three
wound
clip
autoclip
mm
becton
dickinson
germani
anim
place
cage
success
implant
emitt
control
vital
view
softwar
health
statu
control
seven
day
infect
mice
treat
nebulis
extract
mgml
three
time
pm
min
h
control
immedi
treatment
mice
kill
lung
obtain
fix
buffer
paraformaldehyd
lung
stain
haematoxylin
eosin
lectin
stain
lung
section
perform
sambucu
nigra
agglutinin
sna
vector
laboratori
sialic
acid
link
galactos
maackia
amurensi
agglutinin
mal
ii
vector
laboratori
sialic
acid
link
galactos
secondari
stain
perform
abckit
vector
min
rt
substrat
reaction
perform
dab
kit
vector
laboratori
rabi
caus
neurotrop
viru
genu
lyssaviru
famili
rhabdovirida
transmiss
mammal
transmiss
human
inocul
inhal
infecti
viru
suspect
infect
materi
must
handl
appropri
safeti
condit
specifi
world
health
organis
seven
distinct
genet
lineag
distinguish
within
genu
lyssaviru
crossprotect
test
molecular
biolog
analysi
name
classic
rabi
viru
rabv
genotyp
serotyp
lago
bat
viru
lbv
genotyp
serotyp
mokola
viru
mokv
genotyp
serotyp
duvenhag
viru
duuv
genotyp
serotyp
european
bat
lyssavirus
eblv
subdivid
two
biotyp
genotyp
genotyp
australian
bat
lyssaviru
ablv
genotyp
recent
isol
australia
also
member
lyssaviru
genu
yet
classifi
serotyp
virus
serotyp
eblv
ablv
known
rabiesrel
virus
experiment
model
rabi
establish
fruiteat
bat
artibeu
jamaicensi
infect
stabl
variant
right
masset
muscl
produc
neurolog
sign
rabi
paresi
ataxia
inabl
fli
produc
neurolog
sign
bat
sacrif
distribut
rabi
viru
antigen
assess
tissu
section
immunoperoxidas
stain
virus
spread
brain
stem
bilater
trigemin
ganglia
day
dissemin
wide
central
nervou
system
cn
day
involv
spinal
cord
thalamu
cerebellum
cerebr
cortex
infect
neuron
spinal
cord
day
cerebellum
thalamu
cerebr
cortex
day
infect
pyramid
neuron
hippocampu
observ
day
infect
infect
neuron
never
note
hippocampu
infect
infect
mani
neuron
promin
involv
neuron
process
spread
effici
cn
morpholog
chang
apoptosi
biochem
evid
dna
fragment
observ
neuron
either
viru
rout
inocul
differ
neurovirul
properti
cv
variant
model
relat
vivo
abil
induc
apoptosi
test
detect
infect
tissu
suspens
cell
cultur
laboratori
anim
use
fat
give
uncertain
result
fat
neg
case
known
human
exposur
fivetoten
mice
week
old
g
litter
newborn
mice
inocul
intracerebr
recommend
though
strictli
essenti
use
specif
pathogenfre
spf
mice
inoculum
clarifi
supernat
wv
homogen
brain
materi
cortex
ammon
horn
cerebellum
medulla
oblongata
isoton
buffer
solut
contain
antibiot
reduc
anim
pain
mice
anaesthetis
inocul
young
adult
mice
observ
daili
day
everi
dead
mous
examin
rabi
use
fat
street
fox
rabi
strain
death
due
rabi
gener
begin
nine
day
postinocul
faster
result
newborn
mice
possibl
check
one
babi
mous
fat
day
postinocul
vivo
test
quit
expens
particularli
spf
mice
use
avoid
possibl
give
rapid
result
compar
vitro
inocul
test
test
posit
larg
amount
viru
isol
singl
mous
brain
strain
identif
purpos
anoth
advantag
lowtech
test
easili
practic
appli
situat
skill
facil
test
eg
cell
cultur
avail
neuroblastoma
cell
line
atcc
american
type
cultur
collect
use
routin
diagnosi
rabi
cell
grown
dulbecco
modifi
eagl
medium
dmem
foetal
calf
serum
incub
co
sensit
compar
babi
hamster
kidney
cell
cell
line
sensit
street
isol
without
adapt
step
check
suscept
local
predomin
viru
variant
use
presenc
rabi
viru
cell
reveal
fat
result
test
obtain
least
h
one
replic
cycl
viru
cell
gener
incub
continu
h
laboratori
four
day
test
sensit
mous
inocul
test
cell
cultur
unit
exist
laboratori
test
replac
mous
inocul
test
avoid
use
live
anim
less
expens
give
rapid
result
often
advis
carri
one
type
test
sampl
least
human
exposur
current
test
antihiv
drug
hamper
owe
lack
small
anim
readili
avail
easi
handl
infect
system
harbour
major
target
cell
physiolog
frequenc
organ
distribut
activ
state
establish
pharmacolog
model
potenti
outbr
spraguedawley
rat
transgen
express
receptor
complex
cell
macrophag
explor
goffinet
et
al
model
preclin
evalu
inhibitor
target
viru
entri
revers
transcript
rt
observ
concentr
enfuvirtid
peptid
fusion
inhibitor
efavirenz
nonnucleosid
rt
inhibitor
requir
inhibit
infect
cultur
primari
cell
macrophag
human
rat
differ
threefold
requir
human
refer
cultur
prophylact
treatment
doubletransgen
rat
weightadapt
paediatr
dose
either
enfuvirtid
sc
twicedaili
efavirenz
oral
oncedaili
achiev
reduct
respect
cdna
load
spleen
four
day
iv
challeng
oncedaili
dose
enfuvirtid
result
fivefold
weaker
inhibit
infect
studi
provid
proof
hivsuscept
transgen
rat
allow
rapid
predict
preclin
evalu
inhibitori
potenc
pharmacokinet
properti
antivir
compound
target
earli
step
hiv
replic
cycl
gener
initi
characteris
rat
report
cultur
primari
lymphocyt
macrophag
transgen
rat
random
human
donor
gener
mani
worker
viru
stock
provir
dna
clone
directli
brain
tissu
patient
die
aid
dementia
complex
gener
replicationcompet
stock
vivo
infect
studi
viru
stock
characteris
concentr
infecti
titr
tzmbl
iu
keppler
et
al
molecular
clone
e
egfp
carri
egfp
gene
within
nef
locu
roda
e
egfp
rt
mut
v
e
egfp
pseudotyp
vsvg
virion
contain
blamvpr
produc
tripletransfect
cell
calcium
phosphat
dna
precipit
two
day
posttransfect
supernat
concentr
centricon
spin
column
millipor
usa
viru
particl
purifi
sucros
cushion
g
min
virionenrich
pellet
resuspend
medium
store
drug
enfuvirtid
roch
usa
dissolv
mgml
dilut
distil
water
efavirenz
bristolmy
squibb
usa
use
drink
solut
mgml
dilut
pb
flow
cytometri
base
ex
vivo
virionfus
assay
conduct
standard
method
briefli
primari
cell
macrophag
pretreat
indic
concentr
enfuvirtid
min
subsequ
cell
challeng
blamvpr
virion
ng
per
cell
per
macrophag
h
wash
load
dye
overnight
fusion
monitor
threelas
bd
facsaria
cell
sort
system
ex
vivo
efficaci
test
drug
efavirenz
macrophag
pretreat
overnight
cell
h
efavirenz
indic
concentr
subsequ
challeng
singleround
vsvg
egfp
report
virion
ng
per
cell
per
macrophag
day
postinfect
percentag
egfpposit
cell
macrophag
score
flow
cytometri
facscalibur
use
bd
cellquest
pro
softwar
vivo
efficaci
test
two
independ
studi
similar
design
perform
anim
age
week
weight
g
nnrti
studi
group
consist
six
rat
treat
either
efavirenz
mgkg
per
day
pb
oncedaili
oral
gavag
three
day
day
rat
experiment
group
anaesthetis
challeng
tail
vein
inject
plastic
cathet
tzmbl
iu
ng
per
rat
fusion
inhibitor
studi
group
consist
five
six
rat
treat
enfuvirtid
mgkg
per
day
appli
either
twicedaili
oncedaili
sc
inject
control
group
inject
twice
daili
equival
volum
distil
water
day
rat
challeng
iv
tzmbl
iu
ng
per
rat
efficaci
studi
one
hivnonsuscept
transgen
rat
challeng
ident
viru
inoculum
dose
continu
day
postchalleng
anim
kill
total
dna
prepar
singlecel
suspens
splenocyt
use
dneasi
tissu
kit
qiagen
valencia
ca
analys
quantit
duplex
pcr
quantit
dna
speci
amount
total
cdna
circl
splenocyt
extract
analys
quantit
duplex
pcr
abi
sequenc
detect
system
appli
biosystem
usa
amplifi
primer
pair
specif
ltr
gag
probe
fluorescein
fam
cagtggcgcccgaacaggga
rhodamin
tamra
quantit
circl
junction
forward
primer
anneal
revers
primer
anneal
probe
fam
tccacactgactaaaa
gggtctggggatctct
tamra
use
standard
curv
dilut
e
egfp
cover
five
log
use
supplement
dna
uninfect
cell
result
obtain
cdna
speci
normalis
amount
cellular
dna
quantifi
reaction
amplif
rat
gapdh
gene
dna
latter
dilut
genom
dna
extract
primari
rat
cell
use
standard
curv
cycl
programm
min
min
cycl
min
sampl
run
duplic
data
analys
system
softwar
lowest
detect
limit
rang
copi
per
ng
dna
copi
per
ng
dna
total
cdna
circl
respect
hepat
b
remain
major
public
health
problem
worldwid
despit
avail
effect
vaccin
hepat
b
viru
hbv
member
hepadnavirus
hepatotrop
dna
virus
caus
acut
chronic
infect
liver
approxim
hbv
carrier
differ
level
hepatocyt
destruct
could
develop
liver
cirrhosi
hepatocellular
carcinoma
hcc
liver
cancer
million
peopl
chronic
hbv
infect
lifelong
high
risk
develop
cirrhosi
andor
liver
cancer
chronic
carrier
die
complic
chronic
liver
diseas
sever
antivir
drug
approv
treatment
hepat
b
includ
interferong
nucleosid
analogu
howev
unresolv
signific
issu
moder
low
efficaci
dosedepend
side
effect
drug
resist
remain
current
drug
therefor
exist
signific
unmet
medic
need
safe
efficaci
new
antihbv
drug
contrari
natur
product
provid
larg
reservoir
potenti
activ
agent
safer
efficaci
antihbv
agent
recent
studi
polyphenol
extract
geranium
carolinianum
l
hbv
replic
vitro
vivo
human
hbvtransfect
liver
cell
line
hepg
show
effect
suppress
secret
hbv
antigen
dosedepend
manner
ic
mgml
hbsag
mgml
hbeag
day
consist
hbv
antigen
reduct
extract
mgml
reduc
hbv
dna
level
duck
hepat
b
viru
dhbv
infect
duck
intragastricli
ig
day
day
plasma
dhbv
dna
level
reduc
ed
mgkg
addit
southern
blot
analysi
confirm
vivo
antihbv
effect
extract
duck
extract
also
reduc
plasma
liver
dhbv
dna
level
dosedepend
manner
furthermor
signific
improv
liver
observ
extract
treatment
evalu
histopatholog
analysi
anoth
studi
hbvtransfect
liver
cell
line
reveal
wogonin
potent
antiinflammatori
anticanc
dug
isol
tradit
chines
medicin
scutellaria
radix
use
treatment
inflammatori
condit
includ
hepat
reduc
level
hbv
antigen
dna
inhibit
hbv
dna
polymeras
much
higher
potenc
importantli
demonstr
antihbv
activ
vivo
duck
hepat
b
viru
dhbv
infect
duck
human
hbvtransgen
mice
human
hbvtransfect
liver
cell
line
wogonin
effect
suppress
secret
hbv
antigen
hbsag
hbeag
ic
mgml
day
reduc
hbv
dna
level
dosedepend
manner
dhbv
dna
polymeras
dramat
inhibit
wogonin
ic
mgml
dhbvinfect
duck
wogonin
day
day
reduc
plasma
dhbv
dna
level
ed
mgkg
vivo
antihbv
effect
wogonin
duck
confirm
southern
blot
duck
viral
dna
liver
addit
human
hbvtransgen
mice
wogonin
iv
day
day
significantli
reduc
plasma
hbsag
level
antihbv
studi
duckl
dhbvposit
vertic
transmiss
femal
duck
month
old
g
maintain
normal
daylight
fed
standard
commerci
diet
water
ad
libitum
human
hbvtransgen
mice
week
old
posit
plasma
hbsag
lineag
maintain
h
lightdark
cycl
standard
commerci
diet
water
ad
libitum
duckl
one
day
age
intraven
infect
viral
genom
equival
vge
vge
pg
dhbv
seven
day
later
extract
solubilis
isoton
salin
solut
administ
mgkg
daili
oral
liquid
diet
day
isoton
salin
liquid
diet
also
administ
anim
neg
control
lamivudin
mgkg
use
posit
control
dhbv
dna
level
measur
day
cessat
treatment
day
day
dot
blot
analysi
four
gram
duck
liver
tissu
ground
ml
buffer
contain
mm
trishcl
ph
nacl
mm
edta
mgml
sd
mgml
salmon
sperm
dna
mgml
proteinas
k
h
follow
centrifug
g
min
supernat
extract
phenolchloroform
dna
precipit
two
volum
ethanol
volum
acet
acid
dna
dissolv
ml
te
buffer
final
purifi
dna
separ
agaros
gel
analys
southern
blot
analysi
use
dhbv
dna
probe
describ
previous
dhbvposit
duck
treat
ppgc
tc
ig
daili
day
anim
sacrif
liver
tissu
remov
fix
formalin
embed
paraffin
tissu
sampl
slice
mm
section
stain
haematoxylin
eosin
examin
light
microscopi
virusinfect
organ
harvest
sacrif
anim
virus
purifi
either
minc
tissu
treat
colagenas
freezethaw
media
titr
measur
vitro
test
describ
previous
immunofluorecnc
assay
tissu
section
plaqu
reduct
assay
quantit
pcr
indirect
measur
inhibit
viral
infect
also
done
monitor
fever
activ
immun
respons
inflammatori
cytokin
mortal
post
viru
infect
common
viral
diseas
still
fatal
also
upsurg
new
viral
infect
worldwid
current
avail
antivir
though
effect
beyond
mean
develop
countri
thu
develop
safe
effect
inexpens
antivir
drug
like
rt
inhibitor
among
top
global
prioriti
mani
virus
yet
curabl
high
mortal
rate
recent
consider
attent
given
screen
variou
speci
medicin
plant
especi
focu
antihiv
activ
consider
rise
use
counter
medicin
plant
product
contain
orthodox
medicin
drug
rational
reduc
side
effect
produc
synergist
effect
sinc
case
pharmacolog
mechan
combin
well
studi
advers
effect
therapeut
failur
observ
import
consider
involv
medicin
plant
identifi
standardis
exact
method
prepar
extract
appropri
season
collect
plant
materi
detail
administr
sinc
signific
number
plant
extract
yield
posit
result
seem
reason
conclud
probabl
mani
potenti
antivir
agent
characteris
activ
ingredi
reveal
use
compound
